Literature DB >> 1671032

Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function.

J M Cleghorn1, R D Kaplan, B Szechtman, H Szechtman, G M Brown, S Franco.   

Abstract

The authors compare symptoms and neuropsychological test performance in DSM-III schizophrenic patients who reported prior substance abuse (N = 38) with those in patients who reported no such abuse (N = 25) to determine the impact of substance abuse on the psychopathology of schizophrenia. Positive and negative symptom scores were derived from the Schedule for Affective Disorders and Schizophrenia. Sixty neuropsychological measures drawn from commonly used tests of intelligence, memory, learning, fluency, and problem solving were calculated. Separate analyses were performed on patients in a psychotic episode who were free of neuroleptics (N = 27) and on those taking maintenance neuroleptics (N = 36). Among unmedicated patients, those who reported prior substance abuse had significantly higher thought disorder scores. Among neuroleptic-medicated patients, hallucination and delusion scores were significantly higher in the patients who reported prior substance abuse. The substance abuse followed withdrawal from social relations and preceded the onset of positive symptoms. None of the neuropsychological tests discriminated between abusers and nonabusers.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1671032

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  23 in total

Review 1.  Cannabis and psychosis.

Authors:  Louisa Degenhardt; Wayne Hall
Journal:  Curr Psychiatry Rep       Date:  2002-06       Impact factor: 5.285

2.  Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status.

Authors:  Kate B Carey; Michael P Carey; Jeffrey S Simons
Journal:  J Nerv Ment Dis       Date:  2003-05       Impact factor: 2.254

Review 3.  Cannabinoid modulation of noradrenergic circuits: implications for psychiatric disorders.

Authors:  Ana Franky Carvalho; Elisabeth J Van Bockstaele
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-01-24       Impact factor: 5.067

4.  Substance abuse and cognitive functioning in schizophrenia.

Authors:  J Addington; D Addington
Journal:  J Psychiatry Neurosci       Date:  1997-03       Impact factor: 6.186

5.  [Substance use associated disorders: frequency in patients with schizophrenic and affective psychoses].

Authors:  L Hermle; R Szlak-Rubin; K L Täschner; P Peukert; A Batra
Journal:  Nervenarzt       Date:  2013-03       Impact factor: 1.214

6.  Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders.

Authors:  Serge Sevy; Katherine E Burdick; Hema Visweswaraiah; Sherif Abdelmessih; Meredith Lukin; Eldad Yechiam; Antoine Bechara
Journal:  Schizophr Res       Date:  2007-03-26       Impact factor: 4.939

7.  Positive and negative symptoms in families with schizophrenia.

Authors:  A S Bassett; E J Collins; S E Nuttall; W G Honer
Journal:  Schizophr Res       Date:  1993-12       Impact factor: 4.939

Review 8.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

9.  The incremental inpatient costs associated with marijuana comorbidity.

Authors:  Rosalie Liccardo Pacula; Jeanne Ringel; Carlos Dobkin; Khoa Truong
Journal:  Drug Alcohol Depend       Date:  2007-10-10       Impact factor: 4.492

10.  Cannabis use and cognition in schizophrenia.

Authors:  Else-Marie Løberg; Kenneth Hugdahl
Journal:  Front Hum Neurosci       Date:  2009-11-24       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.